Breaking Down NovoCure: 4 Analysts Share Their Views
4 analysts have expressed a variety of opinions on NovoCure (NASDAQ:NVCR) over the past quarter, offering a diverse set of opinions from bullish to bearish.The table below provides a concise overview
Novocure Is Maintained at In-Line by Evercore ISI Group
Novocure Is Maintained at In-Line by Evercore ISI Group
Evercore Maintains Novocure(NVCR.US) With Hold Rating, Raises Target Price to $20
Evercore analyst Vijay Kumar maintains $Novocure(NVCR.US)$ with a hold rating, and adjusts the target price from $14.5 to $20.According to TipRanks data, the analyst has a success rate of 47.4% and a
Novocure to Report Second Quarter 2024 Financial Results
ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial marke
Stocks With the Highest and Lowest Liquidity - Goldman Sachs
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Novocure(NVCR.US) Director Sells US$23,032.85 in Common Stock
$Novocure(NVCR.US)$ Director VERNON W ANTHONY sold 964 shares of common stock on Jun 4, 2024 at an average price of $23.893 for a total value of $23,032.85.Source: Announcement What is statement of ch
Novocure(NVCR.US) Director Sells US$23,025.24 in Common Stock
$Novocure(NVCR.US)$ Director LEUNG GABRIEL sold 964 shares of common stock on Jun 4, 2024 at an average price of $23.8851 for a total value of $23,025.24.Source: Announcement What is statement of chan
Novocure(NVCR.US) Director Sells US$23,027.45 in Common Stock
$Novocure(NVCR.US)$ Director Scannell Timothy J sold 964 shares of common stock on Jun 4, 2024 at an average price of $23.8874 for a total value of $23,027.45.Source: Announcement What is statement of
A Closer Look at 7 Analyst Recommendations For NovoCure
7 analysts have shared their evaluations of NovoCure (NASDAQ:NVCR) during the recent three months, expressing a mix of bullish and bearish perspectives.The table below summarizes their recent ratings,
Novocure Price Target Maintained With a $22.00/Share by HC Wainwright & Co.
Novocure Price Target Maintained With a $22.00/Share by HC Wainwright & Co.
NovoCure Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/04/2024 -8.41% HC Wainwright & Co. $22 → $22 Reiterates Neutral → Neutral 05/02/2024 -8.41% HC Wainwrig
Wedbush Adjusts Price Target on NovoCure to $24 From $21, Maintains Neutral Rating
NovoCure (NVCR) has an average rating of outperform and price targets ranging from $14.50 to $42, according to analysts polled by Capital IQ. Price: 24.01, Change: +0.12, Percent Change: +0.50
Express News | Novocure Ltd : Wedbush Raises Target Price to $24 From $21
Novocure Tumor Treating Fields Decreases Progression of Brain Metastases
Express News | NovoCure Shares Are Trading Higher After the Company Announced That the Phase 3 METIS Trial Met Its Primary Endpoint
Express News | Novocure Reports Presentation Of Clinical Data From Phase 3 METIS Trial; Says Trial Met Its Primary Endpoint, Demonstrating Statistically Significant Improvement In Time To Intracranial Progression
Express News | Novocure Ltd: Preliminary Analyses of Key Secondary Endpoints Did Not Demonstrate Statistical Significance
Express News | Metis Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression With Improved Quality of Life Deterioration-Free Survival
METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression With Improved Quality of Life Deterioration-Free Survival
Novocure (NASDAQ: NVCR) today announced the presentation of clinical data from the phase 3 METIS trial, which investigated the use of Tumor Treating Fields (TTFields) therapy in the treatment of brain metastases from non-small cell lung cancer (NSCLC).